For Science & Industry

The CMT infrastructure your program needs is already built.

The Hereditary Neuropathy Foundation (HNF) has spent more than two decades building the scientific infrastructure that turns Charcot-Marie-Tooth disease (CMT) from an orphan condition into a tractable drug development program. A consented patient registry, a characterized biobank, validated models, FDA-engaged regulatory groundwork, and partnership structures that align the field. The pieces a program usually assembles from scratch are already here, in use, and open to serious teams.

A researcher in gloves uses a pipette to process a donated sample at a CMT Biobank collection event.

One operational stack, not a list of assets

Each component below is a program in its own right, and they are designed to work together: registry data points to the biobank, the biobank feeds target validation, validated endpoints make trials possible, and the regulatory groundwork lowers the risk of getting there. Whether you need natural history data, samples, trial-ready sites, or a regulatory strategy, you are not starting from zero.

By the numbers

6,000+ GRIN participants worldwide

72+ countries represented

4,282+ biospecimens banked

31 Centers of Excellence

As of July 2026.

Explore the infrastructure

GRIN Registry Data Access The IRB-approved, patient-led global registry for CMT, for cohort sizing, endpoint validation, and trial-ready reach. TRIAD Partnership Model How HNF aligns academia, government, and industry around shared CMT priorities. Biobank Access Patient-derived, characterized samples linked to consented registry data for target validation and assay development. Clinical Trial Infrastructure Validated outcome measures, recruitment-ready cohorts, and a pathway from discovery to the clinic. FDA & Regulatory Engagement A Patient-Focused Drug Development meeting on record (2022) and patient-experience evidence the agency recognizes. Contact a Research Partner Tell us where your program sits, and we will route you to the right resource.

Tell us what you are working on

Whether you need natural history data, biobank samples, trial-ready sites, or a regulatory strategy, the fastest path is a conversation. Tell us where your program sits and we will route you to the right resource.

Contact a research partner Explore GRIN data access

Looking at the science from the inside? See Research for the program detail, or how this work reaches patients in Impact →